氟达拉滨联合化疗方案对复发性非霍奇金淋巴瘤的疗效研究

Clinical Study on Fludarabine-based combined chemotherapy in patients with relapsed non-Hodgkins's lymphoma

目的:探讨氟达拉滨为主联合化疗方案对复发性非霍奇金淋巴瘤的临床疗效。方法:用氟达拉滨为主的方案(FMD)化疗复发性非霍奇金淋巴瘤17例,以EPOCH方案化疗14例患者,比较两组疗效。结果:FMD方案化疗有效率为70.6%,高于EPOCH方案的50.0%,但是差异无统计学意义(P>0.05)。FMD化疗方案在对低度恶性组疗效最佳,优于高度恶性组和中度恶性组(P<0.05);对不同临床分期(Ⅰ、Ⅱ、Ⅲ、Ⅳ期)患者和不同免疫细胞分型患者,其有效率无统计学差异(P>0.05)。在各种不良反应中,FMD组白细胞减少率、转氨酶升高率低于EPOCH组(P<0.05)。结论:以氟达拉滨为主联合化疗方案对复发性非霍奇金淋巴瘤的临床疗效好,毒副反应轻,预后良好。

Objective： To study on clinical effects of fludarabine-based combined chemotherapy in treatment of relapsed non-Hodgkins＇s lymphoma （NHL）. Methods： Seventeen patients with relapsed non-Hodgkins＇s lymphoma were treated by fludarabine-based combined chemotherapy （FMD regimen）, and 14 patients were treated by EPOCH regimen as control. Results： The effect rates of FMD and EPOCH regimen were 70.6% and 50.0% without significant difference （P〉0.05）. In FMD regimen, the effect rates were higher in low potential malignancy group than those in high potential malignancy and midrange potential malignancy （P〈0.05）. There were no significant difference in the patients among different clinical stages （ I, II, III and IV） and different immunocyte type （P〉0.05）. However, the leukopenia rate and transaminase heighten rate were lower in FMD regimen than those in EPOCH regimen （P〈0.05）. Conclusions： The therapy effective power of fludarabine combination chemotherapy regimen in patients with non-Hodgkins＇s lymphoma is significant, and adverse effect is slight.